MaxCyte is a commercial cell engineering company that provides proprietary Flow Electroporation technology platforms for discovering, developing, and commercializing cell and gene therapies. The company's ExPERT platform comprises instruments, disposable processing assemblies, consumables, and analytical services that enable high-efficiency delivery of molecules into cells at scales ranging from thousands to tens of billions of cells, supporting seamless progression from research through clinical manufacturing. MaxCyte generates revenue from instrument sales and licenses, consumables, annual licensing fees, and milestone and sales-based payments under strategic platform license agreements with leading biopharmaceutical companies, biotechnology firms, academic centers, and research institutions; the company has over 857 installed instruments globally and benefits from a recurring revenue model grounded in annual licensing, consumables sales, and potential milestone and royalty streams as customer programs advance toward commercialization.